BioAlliance Pharma: a Major Step Forward in the Development of Sitavir(R): European Registration File Submission for the Treatment of Recurrent Orofacial Herpes

RIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to specialty and orphan oncology products, today announced submission of its Sitavir® (acyclovir Lauriad™) European registration dossier through a European decentralized procedure*.